



THE OCULAR IMMUNOLOGY
AND UVEITIS FOUNDATION
Dedicated to Eye Disease Cure and Education

Brighter Vision Weekly Newsletter

SEP 2022

Events

Thank you so much to all of our sponsors, participants and volunteers for making this year's Walk for Vision in both Boston and New Jersey a success! Your contributions bring OIUF closer to our mission of eradicating ocular inflammatory diseases. Together and across both walks, we raised over \$100,000 for ocular inflammatory diseases, and we couldn't do it without your support!





Save Vision
OIUF
Walk for Vision 2022
One Step at a Time

Presenting Sponsor:
 **HORIZON**

Double Star Sponsors:
 **abbvie**  **Mallinckrodt Pharmaceuticals**

Star Sponsor:
 **ani**
Pharmaceuticals, Inc.

Major Sponsor:
 **EYEPOINT**
PHARMACEUTICALS

Walk for Vision Boston
Sunday, August 21st, 2022
Hyatt Regency
Cambridge, Massachusetts
10:30am

Walk for Vision New Jersey
Sunday, September 18th, 2022
Verona Park Boathouse
Verona, New Jersey
10:15am

Register or Donate Online:
walkforvision.rallybound.org
Or Scan the QR Code → 

16th Annual Auction – Awards Benefit

On Saturday, October 22nd, we will be hosting our annual action and awards benefit.

This event will take place at Fairmont Copley Plaza from 7:00 pm – 10:00 pm.



OIUF
THE OCULAR IMMUNOLOGY
AND UVEITIS FOUNDATION

**16th Annual
AUCTION BENEFIT &
AWARDS CEREMONY**

Co-Chairs: Mia's Army & Lauren Freed
SATURDAY, OCTOBER 22, 2022
7:00 - 10:00pm EST • Fairmont Copley Plaza

PLATINUM SPONSOR
 **HORIZON**

ADVANCING FRONTIERS IN OCULAR
IMMUNOLOGY & UVEITIS AWARD SPONSOR
 **Mallinckrodt**
Pharmaceuticals

Dueling Keyboards After Party



10:00 pm to 12:00 am



**BROWSE ITEMS
& REGISTER AT**
OIUF2022.givesmart.com
**OR SCAN THE
QR CODE**

Buy your ticket for live benefit today!

[View Auction Items Here!](#)

Support

Upcoming Uveitis Support Group

The Uveitis/Support Group is a patient education and support resource founded in 1996 by Dr. Foster, Frances Foster MS, NP, John Hurley LISCW, and many patients of Dr. Foster. We have several support group pages dedicated for adults, parents, children, and educators. We hope to educate patients, their family members and friends, and the medical community on ocular inflammatory disease and facilitate the exchange of information, emotional support, and aid between members.

Since the beginning of the pandemic, we are now providing virtual support groups for everyone to take advantage of.

Let's Talk About It- with Frances Foster and a Former OIUF Fellow
November 1st, 2022 7:00 PM EST

Register in advance for this meeting
here!



Education

2022 Ocular Inflammatory Disease Crash Course

Saturday, November 12th
The Confidante Hotel – Miami, FL

The Crash Course Agenda and Room block information
is available below!

2022 Ocular Inflammatory Disease Crash Course:
for Physicians, Patients and Caregivers
Saturday, November 12th • Miami, Florida

Thank you to our supporters!

Gold Supporters
BAUSCH + LOMB **HORIZON**

Silver Supporter
abbvie

Break Supporter
Mallinckrodt Pharmaceuticals

Copper Supporters
ani Pharmaceuticals, Inc. **EYEPOINT PHARMACEUTICALS**

XIPERE
(triamcinolone acetonide
injectable suspension) 40 mg/mL
Post-Course Wet Lab
FREE with in person
registration
for physicians,
residents and fellows

OIUF 2022 Ocular Inflammatory Disease Crash Course

7:00-8:00	Breakfast
8:00-8:05	Introduction
SECTION 1: THE BASICS	
8:05-8:25	What Is Going On Here? The Uveitis New Patient – Stephen Anesi MD
8:25-8:45	How Do I Treat This? The Step Ladder Approach – C. Stephen Foster MD
SECTION 2: MULTI-DISCIPLINARY APPROACH TO OCULAR INFLAMMATORY DISEASES	
8:45-9:00	HLA-B27 Associated Disease (or just Spondyloarthritis)
9:00-9:15	Orbital Inflammatory Disease & Graves Orbitopathy
9:15-9:30	Discussion 1 & 2
9:30-9:45	AM Break
SECTION 3: ANTERIOR SEGMENT FEATURE: SCLEROKERATITIS	
9:45-9:55	Work Up
9:55-10:05	Medical Management
10:05-10:15	Surgical Care - David Chu MD
10:15-10:30	Discussion 3
SECTION 4: POSTERIOR SEGMENT FEATURE: RETINAL VASCULITIS & CME	
10:30-10:40	Work Up - Peter Chang, MD
10:40-10:50	Medical Management - Peter Chang MD
10:50-11:00	Surgical Care
11:00-11:15	Discussion 4
11:15-12:00	Lunch Break
SECTION 5: SECONDARY INFLAMMATION AND MASQUERADES	
12:00-12:10	Ocular Manifestations of Targeted Oncologic Therapy
12:10-12:20	Primer on Primary Vitreoretinal and CNS Lymphoma
12:20-12:30	Epitope Spreading: Possible Role in Secondary Ocular Inflammation
12:30-12:45	Discussion 5
SECTION 6: NEW HORIZONS IN OID	
12:45-12:55	Biologic Therapy - Rajiv Shah MD
12:55-1:05	Drug Delivery Strategies - Thomas Albin MD
1:05-1:15	Role for MIGS in Uveitis
1:15-1:30	Discussion 6
1:30-1:45	PM Break
SECTION 7: IT IS A COMPLICATED WORLD	
1:45-1:55	COVID-19: Effect on OID Management – Drew Philip MD
1:55-2:05	Diabetes and Uveitis - Rajiv Shah MD
2:05-2:15	Discussion 7
SECTION 8: REAL WORLD CONSIDERATIONS	
2:15-2:30	Navigating Insurance & Other Hurdles for OID Treatment - Frances Foster NP
2:30-2:40	Advocacy & Patients – Peter Chang MD, Frances Foster NP
2:40-2:45	Closing Words

Register here TODAY for 2022 Crash Course!

Room Block for OIUF Crash Course

Research

The following studies are our currently **enrolling** studies for ocular inflammatory disease and other ophthalmology related conditions.

Sylentis Dry Eye and Sjogren's Disease Study



This is a phase III study looking at the safety and efficacy of the study drug (eye drop) on treating dry eye in patients that have been diagnosed with Sjogren's Disease. This study lasts between 3-4.5 months with a total of 5 visits.

Tarsier Pharma Anterior Uveitis

This is a phase III randomized, active-controlled, double-masked study to evaluate the safety and efficacy of TRS01 eye drops in the treatment of subjects with active non-infectious anterior uveitis including subjects with uveitis glaucoma. The TRS01 eye-drop will be compared to an FDA approved corticosteroid eye-drop. The study lasts approximately 6 weeks for a total of 5 clinic visits.



Eli Lilly Uveitis Study - Taltz (Ixekizumab)

This is a phase IV 24-week two-armed proof-of-concept exploratory analysis of subcutaneous ixekizumab administration in patients with recalcitrant non-infectious intermediate, posterior, panuveitis, or chronic-steroid dependent anterior uveitis. We will be enrolling 20 patients at MERSI.



YUTIQ Registry

This is a phase IV retrospective registry to collect real-world data on patients that have received YUTIQ. We will be following patients visits and collecting information for up to 5 years after they first get YUTIQ. Anyone who has received a YUTIQ injection qualifies for the study.



Boston Children's Biorepository

This is a collaboration with Boston Children's Hospital to learn more about autoimmune diseases of the eye to improve diagnosis and treatment. Patients with autoimmune eye inflammation and non-inflammatory conditions are able to enroll. Clinical information and biological samples such as blood and discarded eye fluid will be sampled during patient's surgery.



Shop Amazon Smile for OIUF!

Shop amazon smile and choose the Ocular Immunology and Uveitis Foundation as your charity! Amazon will donate 0.5% of your purchases to OIUF.

Always log in under amazon smile when you shop through Amazon to ensure OIUF receives your donation.



[Click Here to Create an Account](#)

If you want to keep up with everything OIUF, please follow us on our social media pages!



THE OCULAR IMMUNOLOGY
AND UVEITIS FOUNDATION
Dedicated to Eye Disease Cure and Education

Keep in Touch!



O.I.U.F. | PO BOX 646, Weston, MA 02493

[Unsubscribe ajustus@mersi.com](mailto:ajustus@mersi.com)

[Update Profile](#) | [Constant Contact Data Notice](#)

Sent by ajustus@oiuf.org in collaboration with



Try email marketing for free today!